CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical and gynecologic oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of ovarian and endometrial cancer.
  
  LEARNING OBJECTIVES

  • Understand available clinical research findings with PARP inhibitors as maintenance therapy after first-line platinum-based chemotherapy for patients with advanced ovarian cancer (OC), and provide appropriate counsel regarding personalized treatment recommendations.
  • Assess available clinical trial data with and newly adapted indications for FDA-endorsed PARP inhibitors for patients with recurrent, platinum-sensitive and multiregimen-refractory OC in order to optimally and appropriately incorporate these agents into current treatment algorithms.
  • Evaluate the biological rationale for and published research data with PARP inhibitors in combination with other systemic therapies, and consider the current and future clinical and research implications of these findings for OC management.
  • Appreciate available clinical research findings with anti-PD-1/PD-L1 antibodies in combination with chemotherapy as first-line treatment for advanced or recurrent endometrial cancer (EC), and consider the current and future role of this novel strategy in the care of patients with microsatellite instability-high/mismatch repair-deficient and microsatellite-stable/mismatch repair-proficient disease.
  • Recognize available data with anti-PD-1/PD-L1 antibodies in combination with agents targeting the VEGF pathway, and select patients with metastatic EC to receive this novel approach.
  • Understand the biological rationale for and available data with PARP inhibitors in combination with immune checkpoint inhibitor therapy for patients with advanced or metastatic EC.
  • Evaluate published clinical research findings documenting the efficacy of HER2-targeted agents and regimens in patients with HER2-overexpressing EC, OC and other gynecologic cancers, and consider the role of various approaches in the management of these diseases.
  • Describe the scientific justification for, published research data with and ongoing studies of novel agents and strategies for OC and EC, and effectively prioritize clinical trial opportunities for eligible patients.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Video Program: Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 2.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.
  
  AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC)
  Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.
  
  Please note, these programs have been specifically designed for the following ABS practice area: complex general surgical oncology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ASCO2024/OvarianEndometrial/Video/CME.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Floor J Backes, MD
  Professor
  Fellowship Director
  Division of Gynecologic Oncology
  Department of Obstetrics and Gynecology
  The Ohio State University College of Medicine
  The James Cancer Hospital and Solove Research Institute
  Columbus, Ohio
  
  Advisory Committees and Consulting Agreements: AstraZeneca Pharmaceuticals LP, BioNTech SE, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, GSK, ImmunoGen Inc, Merck.
  
  Mansoor Raza Mirza, MD
  Chief Oncologist, Rigshospitalet
  Medical Director, NSGO-CTU (Nordic Society of Gynaecological Oncology – Clinical Trial Unit)
  Vice-President 2020-2024, ESGO (European Society of Gynaecological Oncology)
  Faculty, ESMO (European Society of Medical Oncology)
  Scientific Chair, IGCS Congress 2024
  Jury Member, Prix Galien Foundation
  Copenhagen, Denmark
  
  Advisory Committees: Allarity Therapeutics, Karyopharm Therapeutics; Consulting Agreements: Allarity Therapeutics, AstraZeneca Pharmaceuticals LP, BIOCAD, BioNTech SE, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Eisai Inc, Genmab US Inc, GSK, ImmunoGen Inc, Incyte Corporation, Karyopharm Therapeutics, Merck, Mersana Therapeutics Inc, MSD, Novartis, Regeneron Pharmaceuticals Inc, Roche Laboratories Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc, Zai Lab; Contracted Research: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Deciphera Pharmaceuticals Inc, GSK, Merck, Mersana Therapeutics Inc, Nuvation Bio, Tesaro, A GSK Company; Stock Options/Stock — Public Company: Karyopharm Therapeutics.
  
  Ritu Salani, MD, MBA
  Director, Division of Gynecologic Oncology
  Professor, Department of Obstetrics and Gynecology
  UCLA Health
  Los Angeles, California
  
  Advisory Committees: Eisai Inc, GSK, ImmunoGen Inc, Karyopharm Therapeutics, Merck, Regeneron Pharmaceuticals Inc, Seagen Inc.
  
  Brian M Slomovitz, MD
  Professor, OB-GYN, Florida International University
  Director, Gynecologic Oncology
  Co-Chair, Cancer Research Committee
  Mount Sinai Medical Center
  Miami, Florida
  
  Consulting Agreements: Aadi Bioscience, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, ImmunoGen Inc, Merck, Novocure Inc; Speakers Bureau: Seagen Inc; Nonrelevant Financial Relationship: GOG Foundation Inc.
  
  CONTRIBUTING GENERAL MEDICAL/GYNECOLOGIC ONCOLOGISTS
  Eric H Lee, MD, PhD — No relevant conflicts of interest to disclose. Priya Rudolph, MD, PhD — Advisory Committees and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Daiichi Sankyo Inc, Gilead Sciences Inc, Pfizer Inc; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Gilead Sciences Inc, Lilly, Pfizer Inc, Puma Biotechnology Inc, Seagen Inc, Stemline Therapeutics Inc. Lindsay J Willmott, MD — Advisory Committee: OncoC4; Data and Safety Monitoring Board/Committee: Merck; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Eisai Inc, ImmunoGen Inc, Merck, Seagen Inc.
  
  MODERATOR
  Angeles Alvarez Secord, MD, MHSc
  Professor of Obstetrics and Gynecology, Gynecologic Oncology
  Director of Gynecologic Oncology Clinical Trials
  Duke Cancer Institute
  Durham, North Carolina
  
  Clinical Trial Steering Committees (Uncompensated): Aravive Inc (AXLerate trial), CanariaBio Inc (FLORA-5 trial, QPT-ORE-004 trial), F Hoffmann-La Roche Ltd (AtTEnd trial); Contracted Research: AbbVie Inc, Aravive Inc, AstraZeneca Pharmaceuticals LP, CanariaBio Inc, Clovis Oncology, Eisai Inc, Ellipses Pharma, Genentech, a member of the Roche Group, GSK, I-Mab Biopharma, ImmunoGen Inc, Karyopharm Therapeutics, Merck, Mersana Therapeutics Inc, OncoQuest Inc, Seagen Inc, VBL Therapeutics, Zentalis Pharmaceuticals; Data and Safety Monitoring Board/Committee: CanariaBio Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Eisai Inc, GSK, Karyopharm Therapeutics, and Merck.
  
  Release date: June 2024
  Expiration date: June 2025
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.